Literature DB >> 34255818

Relationship between clone metrics and clinical outcome in clonal cytopenia.

Anna Gallì1, Gabriele Todisco2,3, Eulalia Catamo4,5, Cinzia Sala6, Chiara Elena1, Sara Pozzi2, Elisa Bono1,2, Virginia Valeria Ferretti7, Ettore Rizzo8, Elisabetta Molteni2, Silvia Zibellini1, Martina Sarchi2, Emanuela Boveri9, Jacqueline Ferrari1,2, Nicolas Fiorelli1,2, Clara Camaschella6, Paolo Gasparini4,5, Daniela Toniolo6, Mario Cazzola1,2, Luca Malcovati1,2.   

Abstract

Clonal cytopenia of undetermined significance (CCUS) is associated with an increased risk of developing a myeloid neoplasm with myelodysplasia (MN). To identify the features of the mutant clone(s) that is associated with clinical phenotype and progression, we studied the following cohorts of individuals: 311 patients with idiopathic cytopenia of undetermined significance (ICUS), 532 community-dwelling individuals without hematologic phenotype (n = 355) or with unexplained anemia (n = 177), and 592 patients with overt MN. Ninety-two of 311 (30%) patients with ICUS carried a somatic genetic lesion that signaled CCUS. Clonal hematopoiesis (CH) was detected in 19.7% and 27.7% of nonanemic and anemic community-dwelling individuals, respectively. Different mutation patterns and variant allele frequencies (VAFs) (clone metrics parameters) were observed in the conditions studied. Recurrent mutation patterns exhibited different VAFs associated with marrow dysplasia (0.17-0.48), indicating variable clinical expressivity of mutant clones. Unsupervised clustering analysis based on mutation profiles identified 2 major clusters, characterized by isolated DNMT3A mutations (CH-like cluster) or combinatorial mutation patterns (MN-like cluster), and showing different overall survival (HR, 1.8). In patients with CCUS, the 2 clusters had different risk of progression to MN (HR, 2.7). Within the MN-like cluster, distinct subsets with different risk of progression to MN were identified based on clone metrics. These findings unveil marked variability in the clinical expressivity of myeloid driver genes and underline the limitations of morphologic dysplasia for clinical staging of mutant hematopoietic clones. Clone metrics appears to be critical for informing clinical decision-making in patients with clonal cytopenia.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34255818     DOI: 10.1182/blood.2021011323

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?

Authors:  Daniel R Richardson; Amy E DeZern
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.

Authors:  Mithun Vinod Shah; Abhishek A Mangaonkar; Kebede H Begna; Hassan B Alkhateeb; Patricia Greipp; Ahmad Nanaa; Michelle A Elliott; William J Hogan; Mark R Litzow; Kristen McCullough; Ayalew Tefferi; Naseema Gangat; Mrinal M Patnaik; Aref Al-Kali; Rong He; Dong Chen
Journal:  Blood Cancer J       Date:  2022-07-08       Impact factor: 9.812

Review 3.  What Clonal Hematopoiesis Can Teach Us About MDS.

Authors:  Irenaeus C C Chan; Brian J Wiley; Kelly L Bolton
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 4.  Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease.

Authors:  Gregor Hoermann
Journal:  Diagnostics (Basel)       Date:  2022-07-02

5.  Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance.

Authors:  Dragan Jevremovic; Ahmad Nanaa; Susan M Geyer; Michael Timm; Haya Azouz; Cynthia Hengel; Alexander Reberg; Rong He; David Viswanatha; Mohamad E Salama; Min Shi; Horatiu Olteanu; Pedro Horna; Gregory Otteson; Patricia T Greipp; Zhuoer Xie; Hassan B Alkhateeb; William Hogan; Mark Litzow; Mrinal M Patnaik; Mithun Shah; Aref Al-Kali; Phuong L Nguyen
Journal:  Am J Clin Pathol       Date:  2022-10-06       Impact factor: 5.400

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.